Imperative Care is a biotechnology company that develops treatments intended for ischemic or vascular diseases including stroke, pulmonary embolism, and heart disease. Imperative Care was founded in 2015 and is headquartered in Campbell, CA. Striving to take a holistic view of conditions related to vascular disease, Imperative Care aims to research the entire lifecycle of blood-blocking conditions including detection, early disease stages, life-threatening incidents, and recovery.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/25/2024 | Series E-1 | $75MM | $xx.xx | $1.66B | Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
10,918,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital
|
||||||
07/25/2024 | Series E-2 | $50MM | $xx.xx | $1.66B | Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,279,080
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital
|
||||||
07/25/2024 | Series E-3 | $25MM | $xx.xx | $1.66B | Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
3,639,540
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Amed Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, Healthcor, Innovatus Capital Partners, Intai Technology, Montreux Growth Partners, Pura Vida Investments, Rock Springs Capital
|
||||||
07/15/2021 | Series D | $260MM | $xx.xx | $1.35B | Ally Bridge Group, Amed Ventures, Ascension Ventures, Bain Capital Life Sciences, D1 Capital Partners, Delos Capital, Healthcor Investments, Innovatus Capital Partners, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
37,851,216
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Amed Ventures, Ascension Ventures, Bain Capital Life Sciences, D1 Capital Partners, Delos Capital, Healthcor Investments, Innovatus Capital Partners, Rock Springs Capital
|
||||||
11/26/2019 | Series C | $86MM | $xx.xx | $266.49MM | Ally Bridge Group, Ascension Ventures, Bain Capital Life Sciences, Delos Capital, Incept, Rock Springs Capital | |
Price per Share
$xx.xx
Shares Outstanding
43,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Ascension Ventures, Bain Capital Life Sciences, Delos Capital, Incept, Rock Springs Capital
|
||||||
06/23/2017 | Series B | $25.37MM | $xx.xx | $87.32MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
21,500,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
03/24/2017 | Series A | $3.1MM | $xx.xx | $7.75MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
15,500,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
7.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|